The study of cancer genes in mouse models has traditionally relied on genetically-engineered strains made via transgenesis or gene targeting in embryonic stem cells 1 . Here we describe a new method of cancer model generation using the CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated proteins) system in vivo in wild-type mice. We used hydrodynamic injection to deliver a CRISPR plasmid DNA expressing Cas9 and single guide RNAs (sgRNAs) [2] [3] [4] to the liver that directly target the tumour suppressor genes Pten (ref. 5 ) and p53 (also known as TP53 and Trp53) (ref. 6) , alone and in combination. CRISPR-mediated Pten mutation led to elevated Akt phosphorylation and lipid accumulation in hepatocytes, phenocopying the effects of deletion of the gene using Cre-LoxP technology 7, 8 . Simultaneous targeting of Pten and p53 induced liver tumours that mimicked those caused by Cre-loxPmediated deletion of Pten and p53. DNA sequencing of liver and tumour tissue revealed insertion or deletion mutations of the tumour suppressor genes, including bi-allelic mutations of both Pten and p53 in tumours. Furthermore, co-injection of Cas9 plasmids harbouring sgRNAs targeting the b-catenin gene and a single-stranded DNA oligonucleotide donor carrying activating point mutations led to the generation of hepatocytes with nuclear localization of b-catenin. This study demonstrates the feasibility of direct mutation of tumour suppressor genes and oncogenes in the liver using the CRISPR/Cas system, which presents a new avenue for rapid development of liver cancer models and functional genomics.
The prokaryotic type II CRISPR/Cas genome editing tools have been successfully applied in many organisms, including mouse and human cells 2, 4, [9] [10] [11] . The system offers sequence-specific direct editing of DNA; therefore, unlike RNA-interference-based approaches 12 , this method can achieve complete loss-of-function of the encoded protein. In rodent and primate embryonic stem cells or zygotes, CRISPR has been applied to efficiently generate mutant alleles or reporter genes [13] [14] [15] [16] [17] [18] [19] . Our groups have previously shown that in vivo delivery of CRISPR can repair a disease gene in mouse liver 20 . However, generation of somatic cancer mutations in adult animals using CRISPR has not, to our knowledge, been reported.
To investigate the potential of the CRISPR system to directly induce loss-of-function mutations in vivo, we chose to target the tumour suppressor gene Pten, which is a negative regulator of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway 5 . Mutation and genomic loss of Pten has been identified in many types of human cancer 5 and liver-specific knockout of Pten in mice induces lipid accumulation and late-onset liver cancer 7, 8 . We cloned a pX330 vector 9 co-expressing an sgRNA targeting Pten (Pten target sequence 1 in Supplementary Table 1 , termed sgPten) and Cas9. We first showed that sgPten could induce Pten mutations in mouse 3T3 cells following transfection (Extended Data Fig. 1 and Supplementary Table 5 ). To deliver CRISPR to the liver in adult mice, we employed hydrodynamic tail-vein injection ( Fig. 1a ), which can deliver DNA to ,20% of hepatocytes for transient expression 21 . As shown in Fig. 1b , hydrodynamic injection of a luciferase plasmid DNA resulted in liver-specific expression of luciferase in mice. We next injected a cohort of FVB mice (an inbred wild-type mouse strain) with sgPten and an equal number of mice with a pX330 plasmid encoding an sgRNA targeting GFP (sgGFP) as a control. In parallel, we genetically deleted Pten in the liver of Pten-floxed mice 8 (Pten fl/fl ) via tail-vein injection of adenovirus expressing the Cre recombinase (adeno-Cre). Two weeks later, immunohistochemical (IHC) staining of liver sections from five of the sgPten-treated mice using a Pten-specific antibody revealed 3.3 6 0.5% hepatocytes with negative Pten staining, surrounded by Ptenpositive cells (Fig. 1c, d and Extended Data Fig. 2a-c) . Importantly, the liver is composed of a mixture of diploid and polyploid hepatocytes, and we cannot determine the ploidy of the Pten-deficient cells. Thus, they may be a mixture of cells with two or more mutated Pten alleles. A lower percentage (0.4 6 0.1%) of hepatocytes showed intermediate Pten staining (Fig. 1d and Extended Data Fig. 2c ), potentially indicating heterozygous Pten mutation in diploid cells or incomplete mutation in polyploid cells. Coincident with negative Pten staining, we detected elevated staining of phospho-Akt (pAkt), a biomarker of the PI3K pathway activity, in sgPten-treated (n 5 5) and adeno-Cre-injected Pten fl/fl mice (n 5 5) ( Fig. 1c bottom panel and Extended Data Fig. 2d ). Histological analysis and Oil Red O staining at two months showed hepatocytes with lipid accumulation in sgPten-treated FVB mice (n 5 5) and adeno-Cretreated Pten fl/fl mice (Extended Data Fig. 3 ), which is a known phenotype associated with Pten mutation in the liver 7, 8 . These data indicate that in vivo CRISPR-mediated genome editing was able to generate Ptennegative cells in the liver, mimicking liver-specific conditional deletion of Pten in mice.
To confirm that loss of Pten staining and function occurred due to CRISPR-mediated mutation of Pten, we performed deep sequencing on the captured targeted region of Pten locus of total liver genomic DNA. Sequencing revealed that 2.6 6 1.4% of the sequencing reads had insertion or deletion mutations (indels) at the Pten locus in sgPten-treated mice (n 5 5) compared to 0.5 6 0.1% in sgGFP-treated mice (n 5 3, P 5 0.02) ( Fig. 1e ). In the sgPten-treated livers, most of the sequence variants were predicted to cause frameshift mutations as inferred from insertion length and/or phase ( Fig. 1f , g and Extended Data Fig. 4 ). For example, we observed frequent occurrence of 1-nucleotide or 2-nucleotide indels, which would lead to disruption of the Pten reading frame ( Fig. 1f-h and Supplementary Table 4 ). These indels clustered at the predicted sgPteninduced Cas9 cutting site ( Fig. 1h and Extended Data Fig. 4a ), whereas the indels detected in sgGFP samples distribute randomly at low frequency, probably due to background PCR errors or sequencing errors (Extended Data Fig. 4b ). Notably, in five independent mice, the frequency of Pten loss scored by IHC (including both full and partial loss of signal) strongly correlated with the frequency of Pten indels ( Fig. 1i , R 2 5 0.81). These data indicate that for most cells, expression of the sgPten vector results in complete mutation of all Pten alleles present in the cell. Because non-parenchymal cells in the liver generally do not take up DNA following hydrodynamic injection, it is not surprising that the indel frequency in liver genomic DNA and the frequency of Ptennegative hepatocytes are not strictly equal.
To assess the long-term phenotype following sgPten treatment, we harvested livers from three sgPten-treated mice at four months. As shown in Fig. 2a , these livers exhibited regions of hepatocytes with prominent lipid accumulation, loss of Pten and increased pAkt staining, which phenocopies Pten-knockout mice 7, 8 . To address whether sgPten induces p53 in hepatocytes, we performed p53 IHC on sgPten-treated liver sections at 14 days and 4 months. sgPten liver sections did not stain positively for p53, despite elevated pAkt ( Fig. 2a and Extended Data Fig. 5 ), suggesting that Pten loss does not activate the p53 pathway in the liver at these time points. Given the long tumour latency of liver tumours in Pten-knockout mice (44-74 weeks) 7 , we did not observe liver tumours in sgPten-treated mice at time points up to 4 months.
Recent studies identified that Cas9 can tolerate mismatches between sgRNA and genomic DNA depending on the sgRNA sequence and the position of the mismatches 9, 22 . To characterize potential off-target effects of sgPten in the liver, we identified top-ranking sgPten off-target genomic sites in the mouse genome (Extended Data Fig. 6a ) using a published prediction tool 9 . We amplified the Pten locus and the top four potential off-target sites from sgGFP-and sgPten-treated livers and measured CRISPR editing using the Surveyor assay 2 . In the sgPten-treated livers, the assay revealed 2.3 6 0.4% (n 5 2) indels at the Pten locus. In contrast, we did not detect Surveyor nuclease cutting at the assayed offtarget sites (Extended Data Fig. 6b ), indicating that the frequency of off-target editing is below the limit of detection of this assay. Deep sequencing of an sgPten-treated liver sample revealed that the indel frequency within 10-nucleotide regions around the top three predicted cutting sites was ,0.1% (Supplementary Table 6 ).
We next tested a nickase version of Cas9, Cas9(D10A), which only makes single-strand DNA (ssDNA) breaks and was reported to have further reduced levels of off-target effects 23, 24 . We designed a pair of Pten sgRNAs ( Fig. 2b ) predicted to generate off-set ssDNA breaks 24 . The Cas9 D10A plasmid and the two PCR products containing a U6 promoter driving expression of off-set Pten sgRNAs (termed sgPten.2/3) were introduced into FVB mice (n 5 5) by hydrodynamic injection. U6-sgGFP PCR DNA served as a control (n 5 5). By deep sequencing of the liver genomic DNA isolated from two mice at two weeks post-injection, we observed 2.7 6 0.1% indels at the Pten locus in sgPten.2/3-treated mice compared to 0.2 6 0.2% in sgGFP-treated mice (n 5 2) ( Fig. 2c, d and Extended Data Fig. 4c and Supplementary Table 4 ). Pten-negative cells were observed in the sgPten.2/3 livers (2.8 6 0.4%) but not in sgGFP controls (0.0 6 0.0%) by IHC staining ( Fig. 2e ) (n 5 5).
To test whether CRISPR-mediated mutation can target other tumour suppressor genes in vivo, we designed constructs to mutate p53 (also known as TP53 and Trp53), which is the most frequently mutated tumour suppressor gene in human cancer 6 . Exome-sequencing studies have identified frequent mutations of p53 and PTEN in human cholangiocarcinoma 25 . An sgRNA construct targeting p53 was cloned into the pX330 plasmid (termed sgp53) 26 . Transfection of sgp53 into 3T3 cells led to frequent p53 indels, as measured by deep sequencing (Extended LETTER RESEARCH Data Fig. 7 and Supplementary Table 5 ). We next injected a cohort of FVB mice with sgp53 alone. These mice did not exhibit liver tumours at three months post-injection (Extended Data Fig. 8a) , which is consistent with previous studies showing that liver-specific p53-knockout mice develop liver tumours only after 14 months 27 . We also performed deep sequencing of sgp53-treated livers at 14 days and detected 6.0 6 0.1% indels at the p53 locus (Extended Data Fig. 8b and Supplementary Table 4 ), demonstrating that sgp53 can directly generate mutations in p53 in the mouse liver.
In an effort to mutate two tumour suppressor genes simultaneously, we co-injected sgPten and sgp53 into FVB mice (Fig. 3a) . As shown in Fig. 3b and Extended Data Fig. 9 , indels were observed in total liver DNA isolated from two animals, at frequencies of 4.0 6 0.1% for Pten and 6.4 6 0.1% for p53, enriched at the predicted cutting sites. At 3 months post-injection, all 5 mice co-injected with sgPten and sgp53 developed liver tumours with bile duct differentiation features (Fig. 3c ), whereas none of sgGFP-injected mice (n 5 5) developed tumours. The tumours were positive for cytokeratin 19, a marker of bilinear lineage cells 27 (Fig. 3c ). Pten fl/fl ;p53 fl/fl conditional knockout mice (n 5 5) injected with adeno-Cre also developed liver tumours of similar histology at 3 months ( Fig. 3c ). When injected alone, neither sgPten nor sgp53 caused any detectable tumours at this time point. Sequencing of the sgPten-plus sgp53-induced liver tumours and tumour-derived cell lines (n 5 5 tumours analysed) showed bi-allelic mutations of both genes ( Fig. 3d and Supplementary Table 7 ). These results demonstrate that CRISPR-mediated mutation of Pten and p53 can induce liver tumour development, supporting the use of multiplexed CRISPR editing of cancer genes, at least in this tissue. 
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To determine whether CRISPR can be used to directly introduce gainof-function mutations, we targeted the Ctnnb1 gene, which encodes b-catenin, a transcription factor in the Wnt signalling pathway that is frequently mutated in liver cancer 28 . Phosphorylation of four serine/ threonine residues leads to degradation of b-catenin (Fig. 4a) 28 . We co-injected FVB mice with two pX330 plasmids carrying sgRNAs targeting Ctnnb1 (termed sgb-catenin) and a 200-nucleotide ssDNA oligonucleotide containing four point mutations that cause serine/threonine to be replaced with alanine ( Fig. 4a ), which together have been shown to abolish phosphorylation and cause stabilization and nuclear localization of b-catenin (ref. 28) . In mice injected with either sgb-catenin or ssDNA alone (n 5 5), b-catenin was localized only at cell junctions as shown by IHC (Fig. 4b, c ). In contrast, in five mice injected with sgbcatenin and ssDNA, we observed that ,0.5% of hepatocytes exhibited nuclear b-catenin at 7 days post-injection (Fig. 4b, c) . Moreover, accumulation of b-catenin was associated with increased levels of glutamine synthetase, a b-catenin target gene 29 in the liver (Fig. 4c and Extended Data Fig. 10a ) and reduced phospho-b-catenin (Fig. 4d ). In addition, we subjected the liver DNA from two mice treated with this combination to deep sequencing. The data confirm that a small but detectable percentage of sequencing reads contained the four 'G' point mutations present in the ssDNA (Fig. 4e and Extended Data Fig. 10b ). Single-guide b-catenin also generated indels clustered at the predicted Cas9 cutting sites ( Supplementary Table 8 ). These data demonstrate that CRISPR system can be used to directly induce gain-of-function mutation or other substitutions via homologous recombination in vivo 20 .
Our data illustrate the potential to directly disrupt tumour suppressor genes and generate point mutations in oncogenes in adult mouse liver using the CRISPR/Cas system. This method bypasses the need to engineer embryonic stem cells and to breed multiple mutant animals together to generate compound mutants. This approach generated compound Pten and p53 indels at low frequency but was sufficient to induce multifocal tumours. We anticipate that this method will allow for more rapid testing of any single genes or gene combinations that are suspected of being capable of initiating tumour formation in the liver. Given the number of candidate cancer genes being discovered through next generation sequencing efforts, simplified methods of testing the oncogenic properties of candidates in vivo are critical. To increase the sensitivity of the assay, one could perform the CRISPR/Cas9-mediated mutagenesis on a 'sensitized' background carrying constitutive or conditional mutations in a tumour suppressor gene such as p53. More efficient delivery techniques, such as adenovirus or adeno-associated virus (F.A. Ran et al., submitted), more potent sgRNAs, and longer homologous recombination templates might also improve the overall efficiency of this method and expand the range of tissue that could be targeted. Consistent with recent studies showing that long-term Cas9/sgRNA expression is not toxic in cells 26 , hydrodynamic injection of Cas9/sgGFP in mice was well tolerated and did not trigger weight loss in mice 20 . However, further studies are required to fully evaluate the side effects of the CRISPR system in mice and other organisms. This study underscores the power of the CRISPR/Cas9 system for rapid genome editing and the development of novel cancer models in the mouse. 
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METHODS CRISPR vectors. pX330 vector 9 was digested with BbsI and ligated with annealed oligonucleotides ( Supplementary Table 1 ). An extra G is added for sgRNAs lacking a 59 G for U6 transcriptional initiation. Cas9 D10A nickase vector was from addgene 4 . sgPten.2 and sgPten.3 were PCR amplified from empty pX330 plasmid using the U6 forward primer and sgRNA reverse ultramer oligonucleotides 9 (Supplementary  Tables 2 and 3 ) and PCR purified. Mice and hydrodynamic injection. All animal study protocols were approved by the MIT Animal Care and Use Committee. Cohorts of Pten fl/fl and Pten fl/fl ;p53 fl/fl mice were infected with 1 3 10 8 (Fig. 1 ) or 1 3 10 9 (Fig. 3) 33 . Insertions and deletions were crosschecked against reference using VarScan2. Indel phase was calculated as the length of insertions or deletions modulus 3. The rate of b-catenin donor integration was calculated as donor allele frequency. Indels at Pten G304 exist at the same frequency across all samples, thus possibly arise from PCR or sequencing errors, and were filtered out in final analysis. Two to five biological replicates were sequenced for in vivo liver samples. One DNA sample was sequenced for Pten and p53 in 3T3 cells and for Pten off-target sites in sgPten-treated liver. To compare the editing efficiency at Pten off-target sites, the indel frequency within 10-nucleotide regions (20 nucleotides total) flanking Pten A124, OT1 G209, OT2 G451, OT3 G265 was calculated.
Statistics. P values were determined by Student's t-tests and ANOVA for all IHC quantifications. cells is probably a reflection of the transduction efficiency following hydrodynamic injection and the time required to achieve mutation. A recent study by our groups has shown that ,17% of hepatocytes were Flag-Cas9 positive as indicated by IHC 24 h after hydrodynamic injection, only 1.4% of cells on day 7, and less than 0.3% at one month 20 . Given that Cas9-mediated genome editing usually takes more than 48 h (ref.
2), the fraction of hepatocytes that productively express Cas9 and an sgRNA after hydrodynamic injection is estimated to be less than 17%.

